Technical Consultation on the effects of hormonal contraception on bone health
A technical consultation on the effects of hormonal contraception on bone health was convened at WHO in Geneva, Switzerland, 20–21st June, 2005. The consultation brought together the Guidelines Steering Group (GSG), other experts on hormonal contraception, and experts on bone health to evaluate all scientific evidence in this area. Along with the presentation of updated systematic reviews on age and use of hormonal contraceptives, which included evidence on the effects on bone mineral density (BMD) among different age groups, the participants were presented with data on the epidemiology of hormonal contraceptive use, bone health at different life stages, risk of fractures and related morbidity/mortality; risk factors for osteoporosis and fracture; and with unpublished data from a pharmaceutical manufacturer of Depot Medroxyprogesterone Acetate (DMPA). This report summarizes the material presented to participants during the consultation.